Stada has announced that Bryan Kim will from 1 April take over as global head of the firm’s specialty division, a role which includes responsibility for biosimilars and will see him reporting directly to CEO Peter Goldschmidt. The position also includes overseeing Stada’s portfolio and pipeline of prescription brands.
Who’s Hired? Stada Names New Specialty Head
As Hyloris And Slayback Also Reveal New Appointments
Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.
More from Leadership
More from Generics Bulletin
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
• By
Four key areas for policy reform were identified by industry association Medicines for Europe at its biosimilars conference in early April, as sector chair Isabell Remus set out the importance of removing barriers to biosimilar competition.
• By
South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.